

Daniel M Halperin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3886592/daniel-m-halperin-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

2,540
citations

14
h-index

50
g-index

53
ext. papers

3,283
ext. citations

5.9
avg, IF

5
L-index

#	Paper	IF	Citations
47	Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.. <i>Annals of Surgical Oncology</i> , 2022 , 29, 3072	3.1	
46	Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.. <i>Abdominal Radiology</i> , 2022 , 1	3	1
45	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021 , 4, e2131744	10.4	1
44	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021 , 111, 850-862	5.6	1
43	Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021 ,	5.7	14
42	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021 , 11, 2738-2747	24.4	11
41	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4969-e4980	5.6	1
40	FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021 ,	5.6	1
39	Operationalizing Virtual Trials in Oncology-From Aspiration to Action. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 953-957	5.2	1
38	A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. <i>Pharmacoeconomics</i> , 2021 , 39, 1271-1297	4.4	0
37	Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. <i>Journal of Surgical Research</i> , 2021 , 268, 419-431	2.5	
36	Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. <i>Journal of Biomedical Optics</i> , 2020 , 25,	3.5	1
35	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. <i>Endocrine-Related Cancer</i> , 2020 , 27, T9-T25	5.7	3
34	Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2020 , 49, 1123-1130	3.6	4
33	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e117-e123	3.8	4
32	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020 , 49, 863-881	2.6	35
31	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020 , 20, 507-511	2.2	3

30	Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. <i>BMC Cancer</i> , 2019 , 19, 274	4.8	7
29	Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e21006-e21006	2.2	1
28	Direct costs of carcinoid syndrome diarrhea among adults in the United States. <i>World Journal of Gastroenterology</i> , 2019 , 25, 6857-6865	5.6	4
27	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. <i>Pancreas</i> , 2019 , 48, 510-513	2.6	3
26	Management of Diarrhea in Patients With Carcinoid Syndrome. <i>Pancreas</i> , 2019 , 48, 961-972	2.6	17
25	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019 , 48, 381-386	2.6	4
24	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1709-1715	3.1	21
23	Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. <i>BMC Medical Research Methodology</i> , 2018 , 18, 169	4.7	1
22	Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. <i>Medicine (United States)</i> , 2018 , 97, e13390	1.8	3
21	Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. <i>Scientific Reports</i> , 2018 , 8, 16863	4.9	8
20	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. <i>Lancet Oncology, The</i> , 2017 , 18, 525-534	21.7	185
19	Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. <i>Annals of Oncology</i> , 2017 , 28, 1582-1589	10.3	7
18	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. <i>JAMA Oncology</i> , 2017 , 3, 1335-1342	13.4	1391
17	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e300	21.7	1
16	Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?. <i>Clinical Endocrinology</i> , 2017 , 86, 791-797	3.4	4
15	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. <i>Oncologist</i> , 2017 , 22, 1451-1462	5.7	17
14	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017 , 21, 155-163	3.3	27
13	Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. <i>Oncotarget</i> , 2017 , 8, 99541-99551	3.3	31

12	Future Directions in the Biology of Neuroendocrine Tumors. <i>Pancreas</i> , 2016 , 45, 783-5	2.6	2
11	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. <i>Future Oncology</i> , 2016 , 12, 313-21	3.6	3
10	Clinical Trial Design in Neuroendocrine Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 209-17	3.1	3
9	Update on management of midgut neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2016 , 3, 175-189	0.3	4
8	Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2015 , 22, 431-41	5.7	23
7	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2914-9	2.2	2
6	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. <i>Lancet Oncology, The</i> , 2015 , 16, 695-703	21.7	94
5	A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. <i>Annual Review of Medicine</i> , 2015 , 66, 1-16	17.4	23
4	Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?. <i>Current Oncology Reports</i> , 2014 , 16, 366	6.3	19
3	A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. <i>BMC Cancer</i> , 2014 , 14, 561	4.8	13
2	Management of pancreatic neuroendocrine tumors. <i>Gastroenterology Clinics of North America</i> , 2012 , 41, 119-31	4.4	10
1	Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12351-6	11.5	519